Cargando…

Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab

BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matías-Guiu, Jorge, Montero-Escribano, Paloma, Pytel, Vanesa, Porta-Etessam, Jesús, Matias-Guiu, Jordi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286822/ https://www.ncbi.nlm.nih.gov/pubmed/32554284 http://dx.doi.org/10.1016/j.msard.2020.102297

Ejemplares similares

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
por: Montero-Escribano, Paloma, et al.
Publicado: (2020)

Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis
por: Torre‐Fuentes, Laura, et al.
Publicado: (2020)

Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis
por: Delgado-Álvarez, Alfonso, et al.
Publicado: (2021)

Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole‐exome next generation sequencing
por: Pytel, Vanesa, et al.
Publicado: (2019)

Structural MRI correlates of PASAT performance in multiple sclerosis
por: Matias-Guiu, Jordi A., et al.
Publicado: (2018)

Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation
por: Matias-Guiu, Jordi A., et al.
Publicado: (2017)

Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry
por: Matías-Guiu, Jordi A., et al.
Publicado: (2018)

Familial multiple sclerosis and association with other autoimmune diseases
por: Pytel, Vanesa, et al.
Publicado: (2017)

Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task
por: Matias-Guiu, Jordi A., et al.
Publicado: (2020)

Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis
por: Matías-Guiu, Jorge, et al.
Publicado: (2020)

Should we expect neurological symptoms in the SARS-CoV-2 epidemic?()
por: Matías-Guiu, J., et al.
Publicado: (2020)

¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2?
por: Matías-Guiu, J., et al.
Publicado: (2020)

Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation
por: Gomez‐Pinedo, Ulises, et al.
Publicado: (2019)

Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease
por: Gómez-Pinedo, Ulises, et al.
Publicado: (2019)

Factors Associated with the Differences in Migraine Prevalence Rates between Spanish Regions
por: Matias-Guiu, Jorge, et al.
Publicado: (2014)

GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer’s disease and frontotemporal dementia using genetic algorithms
por: García-Gutierrez, Fernando, et al.
Publicado: (2022)

Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging
por: Matías-Guiu, Jordi A., et al.
Publicado: (2016)

Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System
por: Gómez-Pinedo, Ulises, et al.
Publicado: (2021)

Application of Machine Learning to Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study
por: Moral-Rubio, Carlos, et al.
Publicado: (2021)

Management of neurological care during the COVID-19 pandemic()
por: Matías-Guiu, J., et al.
Publicado: (2020)

La gestión de la asistencia neurológica en tiempos de la pandemia de Covid-19
por: Matías-Guiu, J., et al.
Publicado: (2020)

An Online Observational Study of Patients With Olfactory and Gustory Alterations Secondary to SARS-CoV-2 Infection
por: Gómez-Iglesias, Patricia, et al.
Publicado: (2020)

Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study
por: Matías-Guiu, Jordi A., et al.
Publicado: (2015)

Editorial: Consequences of the COVID-19 Pandemic on Care for Neurological Conditions
por: Matias-Guiu, Jordi A., et al.
Publicado: (2021)

Wallenberg’s syndrome and symptomatic trigeminal neuralgia
por: Ordás, Carlos M., et al.
Publicado: (2011)

Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia
por: Matias-Guiu, Jordi A., et al.
Publicado: (2018)

Exosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis
por: Ojeda-Hernández, Doddy Denise, et al.
Publicado: (2022)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

In Vitro Effects of Methylprednisolone over Oligodendroglial Cells: Foresight to Future Cell Therapies
por: Gómez-Pinedo, Ulises, et al.
Publicado: (2023)

Genetic Algorithms for Optimized Diagnosis of Alzheimer’s Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging
por: Díaz-Álvarez, Josefa, et al.
Publicado: (2022)

Predominance of visuoconstructive impairment after mild COVID-19?
por: Díez-Cirarda, María, et al.
Publicado: (2022)

Paroxysmal head pain with backward radiation: will epicrania fugax go in the opposite direction?
por: Cuadrado, María Luz, et al.
Publicado: (2009)

Modelos experimentales de desmielinización-remielinización
por: Torre-Fuentes, L., et al.
Publicado: (2020)

Experimental models of demyelination and remyelination()
por: Torre-Fuentes, L., et al.
Publicado: (2020)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Convivir con Alzheimer /
por: Matías-Guiu Guía, Jordi
Publicado: (2004)

Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach
por: Matias-Guiu, Jorge, et al.
Publicado: (2022)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ttsufj1nht3o4pmr0lgp1nlu5b